Search Results for: 19

Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results

— Received FDA Guidance Following Type-C Meeting to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic HCT Recipients; Enrollment Expected in Q2 2020 — — Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010 for the Treatment of IBS-C — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE, Md.,

Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results Read More »

Synthetic Biologics to Report 2019 Year End Operational Highlights and Financial Results on February 20, 2020

— Conference Call Scheduled for Thursday, February 20, 2020 at 4:30 p.m. ET — ROCKVILLE, Md., Feb. 13, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, intends to report operational highlights

Synthetic Biologics to Report 2019 Year End Operational Highlights and Financial Results on February 20, 2020 Read More »

Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results

— Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C — — Conference Call Today, November 4, 2019, at 4:30 p.m. (EST) — ROCKVILLE, Md., Nov. 4, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent

Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results Read More »

Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019

— Conference Call Scheduled for Monday, November 4, 2019 at 4:30 p.m. ET — ROCKVILLE, Md., Oct. 28, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends

Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019 Read More »

Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results

— Announced Clinical Trial Agreement with Washington University School of Medicine to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients — — Conference Call Today, August 8, 2019, at 4:30 p.m. (ET) — ROCKVILLE, Md., Aug. 8, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company

Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results Read More »

Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019

— Conference Call Scheduled for Thursday, August 8, 2019 at 4:30 p.m. ET — ROCKVILLE, Md., Aug. 1, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational highlights

Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019 Read More »

Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results

— Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 — — Conference Call Today, May 8, 2019, at 4:30 p.m. (ET) — ROCKVILLE, Md., May 8, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that

Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results Read More »